Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Net Margin (2016 - 2023)

Spyre Therapeutics' Net Margin history spans 7 years, with the latest figure at 31552.47% for Q2 2023.

  • For Q2 2023, Net Margin fell 2798079.0% year-over-year to 31552.47%; the TTM value through Mar 2024 reached 52939.68%, down 4626148.0%, while the annual FY2023 figure was 38238.15%, 3463939.0% down from the prior year.
  • Net Margin reached 31552.47% in Q2 2023 per SYRE's latest filing, down from 9304.04% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 56.92% in Q2 2021 to a low of 31552.47% in Q2 2023.
  • Average Net Margin over 3 years is 7632.49%, with a median of 3571.68% recorded in 2022.
  • Peak YoY movement for Net Margin: crashed -351476bps in 2022, then crashed -2798079bps in 2023.
  • A 3-year view of Net Margin shows it stood at 561.09% in 2021, then plummeted by -1897bps to 11203.57% in 2022, then plummeted by -182bps to 31552.47% in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Net Margin are 31552.47% (Q2 2023), 9304.04% (Q1 2023), and 11203.57% (Q4 2022).